Inclusion in major indexes highlights aTyr’s expanding biotech footprint and investor recognition amid advancing therapeutic pipeline.
Inclusion in major indexes highlights aTyr’s expanding biotech footprint and investor recognition amid advancing therapeutic pipeline.
First biologic approved for this rare autoimmune blistering skin disease; pivotal trial data drive swift Priority Review.
Cycle Pharmaceuticals’ CEO calls approval “a defining moment for patients, physicians and science—proving unmet metabolic needs can be …
In late May 2025 a major funding round highlights how investors are backing clinical-stage pipelines together with AI …
Trial halt and valuation collapse trigger major workforce reduction at fibrosis-focused biotech
New research unveiled at the American Association for Cancer Research meeting points to promising treatments for head and …
Phase 2 study for Caliway’s CBL-514 highlights significant progress for Dercum’s disease, a rare and painful condition with …
Funding boost fuels hopes for first disease-modifying treatment in a rare genetic disorder
Australia unveiled a major investment to advance brain cancer clinical research, spotlighting landmark immunotherapy breakthroughs and patient-focused innovation
A key regulation is poised to reshape clinical research in Britain—reducing red tape, elevating patient voices and strengthening …
Already a subscriber? Log in